Skip to Content

Posts tagged with "Drug Prices"

  • Business and Markets

    The Most Unconscionable Drug Price Hike I Have Yet Seen

    There’s a drug called Thiola (tiopronin) that most people have never heard of. It’s on my list of “smaller than aspirin” drugs, and I’d never heard of it until I put that one together. But thanks to a little company called Retrophin, we all get to hear about it now. It’s used to treat cystinuria… Read More
  • Drug Prices

    BioCentury on the Coming Drug Pricing Crisis

    I always enjoy BioCentury‘s “Back to School” issue this time of year, and this time they’re being more outspoken than usual. (That link is free access). The topic is pricing: Last year, (we) argued biopharma companies can no longer assume the market will support premium pricing, even for drugs that deliver meaningful and mea… Read More
  • Cancer

    Incomprehensible Drug Prices? Think Again.

    There’s a post by Peter Bach, of the Center for Health Policy and Outcomes, that’s been getting a lot of attention the last few days. It’s called “Unpronounceable Drugs, Incomprehensible Prices”, and you know what it says. No, really, you do, even if you haven’t seen it. Too high, unconscionable, market can’… Read More
  • Drug Prices

    The Price of Sovaldi

    John LaMattina has a good post about Gilead, their HCV drug Sovaldi, and the price that the company is charging. Most readers here will be familiar with the situation: Sovaldi has a very high cure rate for hepatitis C, but in the US it costs $84,000 per patient. Insurance companies, in some cases, are pushing… Read More
  • Drug Prices

    Another Whack at the Cost of Drugs Issue

    I wanted to highlight this post by Wavefunction on drug pricing. He’s addressing the peole who want to know how come a drug with $X of ingredients in it can sell for some multiple of that price, and I’m glad he’s making the effort. That’s a tough crowd to convince (I’ve taken several swings at… Read More
  • Drug Prices

    Prices Rising – Every Year, Every Drug?

    Via AndyBiotech on Twitter, here’s a disturbing chart of price trends of drugs in several therapeutics areas. Annualized, these are hikes of 10% or more per year. Now, it seems clear that one big reason for this is that hey, insurance will pay for it. And no one needs to tell me (or most readers… Read More
  • Clinical Trials

    Outcomes, Expensive Outcomes

    Well, to go along with that recent paper on confounding cell assays, here’s a column by John LaMattina on the problem of confounding clinical results. For some years now, the regulatory and development trend has been away from surrogate markers and towards outcome studies. You’d think that lowering LDL would be helpful – is it?… Read More
  • Drug Prices

    Catalyst Pharmaceuticals And Their Business Plan

    The orphan-drug model is a popular one in the biopharma business these days. But like every other style of business, it has something-for-nothing artists waiting around it. Take a look at this article by Adam Feuerstein on Catalyst Pharmaceuticals, and see what category you think they belong in. They’re developing a compound called Firdapse f… Read More
  • Business and Markets

    Value For the Money

    BioCentury always does a big issue for the fall, entitled “Back to School”. They often use this as a state-of-biopharma platform, going into depth on what they see as the biggest issues that need to be addressed. This year, the September 2 issue, they’re telling people (and not for the first time!) to get braced… Read More
  • Drug Development

    The Atlantic on Drug R&D

    “Can you respond to this tripe?” asked one of the emails that sent along this article in The Atlantic. I responded that I was planning to, but that things were made more complicated by my being extensively quoted in said tripe. Anyway, here goes. The article, by Brian Till of the New America Foundation, seems… Read More
...567...